M·CAM | Business Events
42
archive,paged,category,category-business-events,category-42,paged-3,category-paged-3,ajax_fade,page_not_loaded,,select-theme-ver-4.1,wpb-js-composer js-comp-ver-7.9,vc_responsive
June 7, 2019 In Business, Business Events

ETF Of The Week: Trade War Fund Arrives

TWAR is ETF of the Week on ETF.com!

Setting aside whether or not tariffs are good trade policy, prolonged tariffs will have drastic impacts on the U.S. economy, as companies are forced to raise their prices to compensate for higher raw goods prices.
What’s bad for the U.S. consumer could be good for ETF investors, however.
Earlier this week saw the timely launch of a new ETF designed specifically to benefit from a prolonged tariff fight: the Innovation α Trade War ETF (TWAR)

It is our great pleasure to be featured as ETF of the week on ETF.com. Whether you put it down to incredible forsight or fortuitousness (we of course think it is a healthy mix of both), we could not have picked a better week to launch!

Read the full piece here

MCAM launch press collage
June 6, 2019 In Business, Business Events, News Archive

M·CAM’s ETF launch covered around the world: Australian Financial Review

“There’s now a trade war ETF you can invest in”

Our ETF launches have now been covered around the whole world – spreading faster than we can keep up. Outside of our main market, the US, we have seen articles appear in Korean, Chinese and Italian.

Now the AFR has published an article on our launch, which we are very happy to see, as we are looking to make a large impact on the superannuation market in Australia.

See the full article in the Australian Financial Review here

June 5, 2019 In Business, Business Events, News Archive

Bloomberg: There’s Now a Trade War ETF You Can Invest In

“The Innovation Alpha Trade War ETF, which started trading on Wednesday under the ticker TWAR, plans to buy companies that have government contracts, calculating that state support could buoy these stocks if tensions escalate. Only firms with strong intellectual property — as defined by M-CAM — are eligible for the fund. “

Bloomberg has this afternoon published a short piece about our TWAR ETF, in light of the launch today.

TWAR is currently trading at $25.77

Read the full article on Bloomberg.com here

March 22, 2019 In Business Events, News Archive, Patently Obvious®

Patently Obvious® – Spandex Rumble Down Under

Several Australian news outlets have recently reported a story interviewing Carolyn Taylor, who alleges that Lorna Jane has infringed on her patent for compression tights filed in 2009. Is this a classic underdog story, where the little guy has been exploited and swept under the carpet by their bigger competitor, or is there more to it? With litigation proceedings set to commence on the 3rd of May, we take a closer look. How far has innovation really wandered from the corsets used in the brothels of Europe?

 

 

” For those new to the patent world, here is some background to the frivolous patent litigation scene: After a famous case involving the University of California and Microsoft, the long dormant eggs containing troll embryos hatched. When trolls feed, they observe goat passages across heavily trafficked bridges, and install toll booths with the cunning aid of men (and precious few women) in wigs and robes. By making the cost of litigation a burden on genuine businesses, these parasites can suck blood from active businesses and unsuspecting consumers. With the cost of litigation in both time and money extremely high, it is not uncommon for patent opportunists to select a single target with whom litigation or settlement is considered likely to build a war chest for going after much larger targets.”

 

Download the full report here

Patent review can be quite cheeky at times. Diagram from US 7260961. Stylistic throwback to the European brothels of yore

February 14, 2019 In Business Events, News Archive, Patently Obvious®

Catalyst Pharmaceutical’s Firdapse price hike – Patently Obvious®

3,4-DAP

Image courtesy: Edgar181 [Public domain], from Wikimedia Commons

 

 

 

Senator Bernie Sanders wrote an open letter to Catalyst Pharmaceuticals on the 4th of February regarding their newly FDA approved drug to treat Lambert-Eaton Myasthenic Syndrome, saying “Catalyst’s decision to set the annual list price at $375,000 is not only a blatant fleecing of American taxpayers, but is also an immoral exploitation of patients who need this medication.”

Seeing this, M·CAM decided to investigate. What follows is a report on a company that has leveraged the patent system and orphan drug act against their intended use to profit on the suffering of vulnerable patients.

Download the Patently Obvious® report here